Preparing for phase II/III HIV vaccine trials in Africa
- 30 November 2005
- journal article
- review article
- Published by Elsevier BV in Microbes and Infection
- Vol. 7 (14), 1436-1444
- https://doi.org/10.1016/j.micinf.2005.07.021
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequencesVaccine, 2005
- Development of an AIDS vaccine: perspective from the South African AIDS Vaccine InitiativeBMJ, 2004
- Impact of intrapeptide epitope location on CD8 T cell recognitionAIDS, 2004
- Sequence Conservation and Antibody Cross‐Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV‐1–Infected Italians, Ugandans, and South AfricansThe Journal of Infectious Diseases, 2003
- Moving to Human Immunodeficiency Virus Type 1 Vaccine Efficacy Trials: Defining T Cell Responses As Potential Correlates of ImmunityThe Journal of Infectious Diseases, 2003
- The Development of HIV‐1 Subtype C Vaccines for Southern AfricaIUBMB Life, 2002
- Assessment of Antibody Assays for Identifying and Distinguishing Recent from Long-Term HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2001
- Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNAScience, 1998
- ESCAPE OF HUMAN IMMUNODEFICIENCY VIRUS FROM IMMUNE CONTROLAnnual Review of Immunology, 1997
- Immune activation is a dominant factor in the pathogenesis of African AIDSImmunology Today, 1995